For people diagnosed with advanced breast cancer, new targeted therapies are offering more personalized paths forward. Truqap is the brand name for capivasertib, a medication that received capivasertib fda approval for specific genetic mutations. Understanding what this drug is and who it may help could be an important step in your care journey. Below, we cover key facts about this treatment option and how it fits into modern oncology.
What Is Truqap (Capivasertib)?
Truqap is a prescription medicine known by its generic name, capivasertib. It belongs to a class of drugs called AKT inhibitors, which target a specific protein involved in cancer cell growth. For certain patients with advanced or metastatic breast cancer, this targeted approach may offer a different way to manage the disease compared to traditional chemotherapy.
How Capivasertib Works in the Body
Capivasertib works by blocking the activity of a protein called AKT, which helps cancer cells survive and multiply. In some breast cancers, genetic changes cause this pathway to be overactive. By inhibiting AKT, capivasertib may slow or stop the growth of these cancer cells. This is especially relevant for tumors with alterations in the PIK3CA, AKT1, or PTEN genes. Your doctor can test for these alterations to see if this treatment might be appropriate.
FDA Approval and Eligible Patients
The U.S. Food and Drug Administration (FDA) approved Truqap in combination with fulvestrant for adults with hormone receptor-positive, HER2-negative advanced breast cancer that has specific genetic changes and has progressed after at least one other endocrine-based therapy. This approval was based on clinical evidence showing meaningful benefit in this subgroup. Key factors your oncologist may consider when evaluating this treatment option include:
- Confirmation of the specific PIK3CA, AKT1, or PTEN mutation via an FDA-approved test
- History of prior treatments for advanced disease
- Overall health and treatment goals
- Potential benefits and risks as explained by your healthcare provider
What to Consider When Discussing Truqap with Your Doctor
As with any cancer therapy, the decision to use capivasertib is made after a thorough evaluation. Your oncologist will review your medical history, previous treatments, and specific tumor characteristics. Because this is a targeted therapy, it is not suitable for all breast cancer patients. Open conversations about your expectations and any concerns can help you determine if this option aligns with your care plan. Regular follow-up appointments allow your care team to assess how well the treatment is working and adjust the plan as needed.
Learn More About Truqap
For certain patients with advanced breast cancer, Truqap (capivasertib) represents a meaningful step forward in targeted treatment. Its capivasertib fda approval marks an important milestone for those whose tumors have specific genetic alterations. If you or a loved one is navigating advanced breast cancer, consider asking your healthcare team about genetic testing and whether this therapy might be an option. Understanding your choices can help you make more informed decisions.